MX2016012722A - Metodos para tratar el virus de la hepatitis c. - Google Patents

Metodos para tratar el virus de la hepatitis c.

Info

Publication number
MX2016012722A
MX2016012722A MX2016012722A MX2016012722A MX2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A MX 2016012722 A MX2016012722 A MX 2016012722A
Authority
MX
Mexico
Prior art keywords
treatment
methods
weeks
compound
pharmaceutically acceptable
Prior art date
Application number
MX2016012722A
Other languages
English (en)
Inventor
M Bernstein Barry
J Podsadecki Thomas
Dutta Sandeep
Wang Tianli
Liu Wei
L Campbell Andrew
M Menon Rajeev
Wei LIN Chih-
AWNI Walid
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2016012722A publication Critical patent/MX2016012722A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención caracteriza terapias libres de interferón para el tratamiento del VHC. Preferiblemente, el tratamiento es sobre una duración más corta de tratamiento, tal como no más de 12 semanas. En un aspecto, el tratamiento comprende administrar al menos dos agentes antivíricos de acción directa y ribavirina a un sujeto con la infección del VHC, en donde el tratamiento tiene una duración de 12 semanas y no incluye administración de interferón, y al menos los dos agentes antiviricos de acción directa comprenden (a) Compuesto 1 o una sal farmacéuticamente aceptable del mismo y (b) Compuesto 2 o una sal farmacéuticamente aceptable del mismo.
MX2016012722A 2014-04-02 2015-04-01 Metodos para tratar el virus de la hepatitis c. MX2016012722A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461973930P 2014-04-02 2014-04-02
US201461989953P 2014-05-07 2014-05-07
US201462016460P 2014-06-24 2014-06-24
PCT/US2015/023922 WO2015153792A1 (en) 2014-04-02 2015-04-01 Methods for treating hcv

Publications (1)

Publication Number Publication Date
MX2016012722A true MX2016012722A (es) 2016-12-16

Family

ID=52875323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012722A MX2016012722A (es) 2014-04-02 2015-04-01 Metodos para tratar el virus de la hepatitis c.

Country Status (8)

Country Link
US (1) US20160317603A9 (es)
EP (1) EP3125890A1 (es)
JP (2) JP6559701B2 (es)
CN (1) CN106456621A (es)
AU (2) AU2015240753B2 (es)
CA (1) CA2943054A1 (es)
MX (1) MX2016012722A (es)
WO (1) WO2015153792A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
CN112704726A (zh) 2014-04-02 2021-04-27 艾伯维公司 治疗hcv的方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
WO2019074507A1 (en) * 2017-10-12 2019-04-18 Abbvie Inc. METHODS FOR THE TREATMENT OF HCV

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003900553A0 (en) * 2003-02-10 2003-02-20 Borody, Thomas Julius Novel Improved Method for Detection of Dientamoeba fragilis and other Parasites
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
AU2013318302B2 (en) * 2012-09-18 2018-02-22 Abbvie Inc. Methods for treating hepatitis C
JP2015528512A (ja) * 2012-09-18 2015-09-28 アッヴィ・インコーポレイテッド Ｃ型肝炎を治療するための方法
NZ719137A (en) * 2013-03-14 2017-11-24 Abbvie Inc Combination of two antivirals for treating hepatitis c
KR20180045055A (ko) * 2013-03-14 2018-05-03 애브비 인코포레이티드 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제
CN112704726A (zh) * 2014-04-02 2021-04-27 艾伯维公司 治疗hcv的方法

Also Published As

Publication number Publication date
JP2017509674A (ja) 2017-04-06
CN106456621A8 (zh) 2017-07-04
US20160317603A9 (en) 2016-11-03
AU2015240753B2 (en) 2020-01-16
AU2020202560A1 (en) 2020-05-07
AU2015240753A1 (en) 2016-09-29
JP6559701B2 (ja) 2019-08-14
US20150283199A1 (en) 2015-10-08
EP3125890A1 (en) 2017-02-08
CA2943054A1 (en) 2015-10-08
CN106456621A (zh) 2017-02-22
JP2019214578A (ja) 2019-12-19
WO2015153792A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
PH12014500833A1 (en) Methods for treating hcv
MX2018000240A (es) Metodos para tratar el vhc.
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2020001422A (es) Metodos para el tratamiento de hcv.
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
AU2019384793A8 (en) Methods for treating acute HCV
MX2018000213A (es) Metodos para tratar el vhc.
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
UA101772U (uk) Спосіб лікування хронічного вірусного гепатиту с із супутньою неалкогольною жировою хворобою печінки
UA104615U (uk) Спосіб лікування токсокарозу
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc
RU2012121337A (ru) Способ лечения животных при ассоциативных инфекционных болезнях различной этиологии